<p>Aerovate Therapeutics, Inc.（納斯達克代碼：AVTE - 獲取免費報告）在週一的期權交易中成為異常活躍的目標。投資者購買了 9,373 份該公司的看漲期權。這比典型的 392 份看漲期權的交易量增加了 2,291%。</p>
<p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金最近對該股票的持倉進行了調整。道富集團在第三季度將其在 Aerovate Therapeutics 的持股增加了 7.7%。道富集團目前擁有 367,468 股該公司的股票，價值 768,000 美元，此前在上個季度增持了 26,278 股。巴克萊銀行在第三季度將其在 Aerovate Therapeutics 的股份提高了 310.8%。巴克萊銀行目前擁有 18,972 股該公司的股票，價值 39,000 美元，此前在上個季度增持了 14,354 股。FNY 投資顧問公司在第四季度購買了 Aerovate Therapeutics 的新股份，價值 198,000 美元。Deltec 資產管理公司在第四季度購買了 Aerovate Therapeutics 的新股份，價值 514,000 美元。最後，Ieq Capital LLC 在第四季度獲得了 Aerovate Therapeutics 的新持倉，價值約 38,000 美元。</p>
<h2>Aerovate Therapeutics 價格表現</h2>
<p>週一中午交易中，AVTE 的股價上漲了 0.01 美元，達到 2.69 美元。該公司交易了 586,168 股股票，而其平均交易量為 613,099 股。Aerovate Therapeutics 的 52 周低點為 1.25 美元，52 周高點為 25.29 美元。該公司的 50 日簡單移動平均線為 2.53 美元，200 日簡單移動平均線也為 2.53 美元。該股票的市值為 7782 萬美元，市盈率為-0.90，貝塔值為 0.95。</p>
<p>Aerovate Therapeutics（納斯達克代碼：AVTE - 獲取免費報告）最後一次發佈財報是在 4 月 25 日，星期五。該公司報告本季度每股收益為（0.09 美元），超出市場共識預期的（0.30 美元）0.21 美元。股票研究分析師預測 Aerovate Therapeutics 在當前年度的每股收益將為-2.64 美元。</p>
<h2>Aerovate Therapeutics 股息公告</h2>
<p>該公司最近還宣佈了一項股息，將於 4 月 28 日，星期一支付。4 月 25 日，星期五的股東將獲得 2.40 美元的股息。該股息的除息日期為 4 月 29 日，星期二。</p>
<h2>Aerovate Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種乾粉吸入劑型的伊馬替尼，用於治療肺動脈高壓，目前處於 2b/3 期臨牀試驗中。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Aerovate Therapeutics 更好</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>2025 年最佳防禦類股票... 到目前為止</li>
<li>投資石油股票的方式和原因</li>
<li>字母表在強勁財報和回購公告後反彈</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克何時關閉</li>
<li>出售台積電會是巴菲特最大的遺憾嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
<p>在你考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買... 而 Aerovate Therapeutics 並不在名單上。</p>
<p>雖然 Aerovate Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVTE

<p>Aerovate Therapeutics, Inc.（納斯達克代碼：AVTE - 獲取免費報告）在週一成為異常大量期權交易活動的目標。股票投資者購買了 9,373 份看漲期權。這比平均交易量 392 份看漲期權增加了約 2,291%</p>

<p>Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading on Monday. Investors bought 9,373 call options on the company. This is an increase of 2,291% compared to the typical volume of 392 call options.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.（納斯達克代碼：AVTE - 獲取免費報告）在週一的期權交易中成為異常活躍的目標。投資者購買了 9,373 份該公司的看漲期權。這比典型的 392 份看漲期權的交易量增加了 2,291%。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of Aerovate Therapeutics by 7.7% during the 3rd quarter. State Street Corp now owns 367,468 shares of the company's stock valued at $768,000 after acquiring an additional 26,278 shares in the last quarter. Barclays PLC lifted its stake in Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock valued at $39,000 after acquiring an additional 14,354 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Aerovate Therapeutics during the fourth quarter worth $198,000. Deltec Asset Management LLC bought a new stake in Aerovate Therapeutics in the 4th quarter valued at $514,000. Finally, Ieq Capital LLC acquired a new position in shares of Aerovate Therapeutics in the fourth quarter valued at about $38,000.</p>
<div class="lb-trans"><p>一些對沖基金最近對該股票的持倉進行了調整。道富集團在第三季度將其在 Aerovate Therapeutics 的持股增加了 7.7%。道富集團目前擁有 367,468 股該公司的股票，價值 768,000 美元，此前在上個季度增持了 26,278 股。巴克萊銀行在第三季度將其在 Aerovate Therapeutics 的股份提高了 310.8%。巴克萊銀行目前擁有 18,972 股該公司的股票，價值 39,000 美元，此前在上個季度增持了 14,354 股。FNY 投資顧問公司在第四季度購買了 Aerovate Therapeutics 的新股份，價值 198,000 美元。Deltec 資產管理公司在第四季度購買了 Aerovate Therapeutics 的新股份，價值 514,000 美元。最後，Ieq Capital LLC 在第四季度獲得了 Aerovate Therapeutics 的新持倉，價值約 38,000 美元。</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 價格表現</h2>
</div><p>Shares of AVTE traded up $0.01 during mid-day trading on Monday, reaching $2.69. 586,168 shares of the company's stock were exchanged, compared to its average volume of 613,099. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $25.29. The business's fifty day simple moving average is $2.53 and its 200-day simple moving average is $2.53. The stock has a market capitalization of $77.82 million, a PE ratio of -0.90 and a beta of 0.95.</p>
<div class="lb-trans"><p>週一中午交易中，AVTE 的股價上漲了 0.01 美元，達到 2.69 美元。該公司交易了 586,168 股股票，而其平均交易量為 613,099 股。Aerovate Therapeutics 的 52 周低點為 1.25 美元，52 周高點為 25.29 美元。該公司的 50 日簡單移動平均線為 2.53 美元，200 日簡單移動平均線也為 2.53 美元。該股票的市值為 7782 萬美元，市盈率為-0.90，貝塔值為 0.95。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.21. Equities research analysts predict that Aerovate Therapeutics will post -2.64 earnings per share for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（納斯達克代碼：AVTE - 獲取免費報告）最後一次發佈財報是在 4 月 25 日，星期五。該公司報告本季度每股收益為（0.09 美元），超出市場共識預期的（0.30 美元）0.21 美元。股票研究分析師預測 Aerovate Therapeutics 在當前年度的每股收益將為-2.64 美元。</p>
</div><h2>Aerovate Therapeutics Dividend Announcement</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 股息公告</h2>
</div><p>The business also recently announced a dividend, which will be paid on Monday, April 28th. Shareholders of record on Friday, April 25th will be given a $2.40 dividend. The ex-dividend date of this dividend is Tuesday, April 29th.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項股息，將於 4 月 28 日，星期一支付。4 月 25 日，星期五的股東將獲得 2.40 美元的股息。該股息的除息日期為 4 月 29 日，星期二。</p>
</div><h2>Aerovate Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發能夠改善美國罕見心肺疾病患者生活的藥物。它專注於推進 AV-101，這是一種乾粉吸入劑型的伊馬替尼，用於治療肺動脈高壓，目前處於 2b/3 期臨牀試驗中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Best Defense Stocks in 2025... So Far</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Alphabet Rebounds After Strong Earnings and Buyback Announcement</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Aerovate Therapeutics 更好</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>2025 年最佳防禦類股票... 到目前為止</li>
<li>投資石油股票的方式和原因</li>
<li>字母表在強勁財報和回購公告後反彈</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克何時關閉</li>
<li>出售台積電會是巴菲特最大的遺憾嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aerovate Therapeutics 嗎？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Aerovate Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買... 而 Aerovate Therapeutics 並不在名單上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aerovate Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

投資者大量買入 Aerovate Therapeutics（NASDAQ:AVTE）的看漲期權